Tag Archives: Launch

Diabetes Drug Launch 2012: Tip-tops and Promo-flops

With Halloween candy flooding the shelves in pharmacies across the nation, it’s only appropriate that we turn the conversation toward an ever-growing drug market and therapeutic area: diabetes.
Posted in Advertising, E-Media, FDA, Marketing, Meetings, Strategy | Also tagged , , , , | 1 Comment

Sanofi's Aubagio to Square Off Against MS Injectables

The most obvious competitors for Sanofi’s Aubagio, the second oral multiple sclerosis (MS) drug to receive FDA approval, would appear to be Novartis’ Gilenya, and Biogen Idec’s hotly anticipated BG-12, which has a PDUFA date scheduled for December 28. Both Gilenya and BG-12 are administered orally as opposed to injected, but execs at Genzyme – […]
Posted in FDA, pricing, Regulatory, Safety, Strategy | Also tagged , , , | 2 Comments

Using Social Networks to Increase Sales

Social networks existed long before Mark Zuckerberg came along. What hasn’t existed until recently are the tools, metrics and case studies necessary to understand how physicians influence each other within professional networks, and how these relationships can be used to change prescribing behavior.
Posted in Advertising, leadership, Marketing, Sales, social media, Strategy, Technology | Also tagged , , , , , , , , , | Leave a comment

Lilly's Decentralized Global Launch Strategy

Global headquarters may get the strategic ball rolling for a new drug launch, but Lilly’s affiliates are responsible for bringing home the bacon, according to a Lilly global brand director.
Posted in Global, leadership, Market Access, Strategy | Also tagged | Leave a comment

First Orphan Launch a Challenge for AstraZeneca

Four months after AstraZeneca received FDA approval for vandetanib, a treatment for inoperable medullary thyroid cancer, the company announced the drug’s trade name: Caprelsa. FDA said other proposed names – Zactima, for example – too closely resembled other currently marketed proprietary names. Getting FDA approval on a brand name for vandetanib, AstraZeneca’s very first orphan drug, […]
Posted in FDA, Marketing, patient education, Safety, Strategy | Also tagged , , , , | Leave a comment
  • Categories

  • Meta